Zacks Investment Research Downgrades Signal Genetics Inc (SGNL) to Sell
Signal Genetics Inc (NASDAQ:SGNL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company’s flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York. “
Separately, Rodman & Renshaw set a $4.00 price objective on Signal Genetics and gave the stock a “buy” rating in a research note on Sunday, August 21st.
Signal Genetics (NASDAQ:SGNL) opened at 0.4875 on Wednesday. Signal Genetics has a 1-year low of $0.40 and a 1-year high of $1.24. The firm’s market cap is $5.26 million. The firm has a 50-day moving average price of $0.50 and a 200-day moving average price of $0.52.
About Signal Genetics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Signal Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.